The ANKRD40 Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population in which the ANKRD40 gene has been disrupted within the HT29 colorectal adenocarcinoma epithelial cell line, providing a loss-of-function model for investigating mTORC1 regulatory networks. This polyclonal knockout pool retains the inherent genetic heterogeneity of the HT29 background while eliminating ANKRD40 expression, enabling robust analysis of dosage-sensitive signaling effects and population-level responses. The knockout product is suitable for applications requiring a genetically defined background where ANKRD40??s inhibition of mTORC1 is ablated, and it is compatible with standard cell culture protocols, antibiotic selection if required, and downstream functional assays.
The HT29 host cell line originates from a primary colorectal adenocarcinoma and harbors well-characterized oncogenic mutations including APC truncation and the BRAF V600E activating mutation, while expressing wild-type p53. These molecular features render HT29 cells a widely employed model for colorectal cancer biology, particularly for studying Wnt pathway dysregulation and MAPK pathway addiction, as well as epithelial barrier function and differentiation. The colorectal adenocarcinoma epithelial phenotype closely mirrors the tumor microenvironment??s characteristics, enabling translational investigations of signaling crosstalk, therapeutic responses, and mechanisms of malignancy in a human-relevant system.
ANKRD40 functions as a direct negative regulator of mechanistic target of rapamycin complex 1 (mTORC1) by physically interacting with the mTOR kinase and its adaptor protein Raptor (RPTOR), thereby attenuating mTORC1 kinase activity. Disruption of ANKRD40 removes this inhibitory constraint, leading to hyperactivation of mTORC1 and consequent increased phosphorylation of downstream effectors S6K1 and 4EBP1, which drive ribosome biogenesis and cap-dependent translation. This signaling cascade also suppresses autophagy through mTORC1-mediated inhibition of the ULK1 initiation complex and nuclear exclusion of the transcription factor TFEB, a master regulator of lysosomal biogenesis and autophagic gene expression. Additionally, ANKRD40 loss may modulate amino acid sensing inputs to mTORC1, though upstream regulators remain uncharacterized. The pathway interplay positions ANKRD40 at a critical junction linking nutrient-sensing to cell growth, autophagy, and cell cycle progression.
In the HT29 colorectal adenocarcinoma context, ANKRD40 knockout generates a model where elevated mTORC1 signaling cooperates with pre-existing APC and BRAF oncogenic lesions to accentuate neoplastic phenotypes. The loss of ANKRD40 further enhances cell proliferation and migration, mirroring aggressive colorectal cancer behavior, and provides a platform for dissecting how mTORC1 hyperactivation intersects with Wnt/??-catenin and MAPK cascades. This engineered model is particularly useful for examining therapeutic resistance mechanisms, as mTORC1 overactivity is associated with reduced sensitivity to BRAF inhibitors and other targeted agents. Researchers can exploit this system to evaluate mTORC1-targeted interventions or screen for synthetic lethal interactions in a genetically defined colorectal cancer background.
This polyclonal knockout cell product supports a wide range of experimental modalities, including western blotting for phospho-S6K1 to confirm mTORC1 pathway activation, cell proliferation and migration assays to quantify functional outcomes, colony formation assays for anchorage-dependent growth, and autophagy flux measurements using LC3 turnover or tandem fluorescent reporters. Transcriptomic profiling via RNA-seq can reveal global gene expression changes downstream of mTORC1 dysregulation. The model is applicable to studies of mTOR signaling, autophagy regulation, cell cycle control, amino acid sensing, and drug resistance in colorectal cancer. For additional product details or technical support, please contact Ascent Research.
